Clinical Nurse Specialist in Silver Spring, MD Accepting Medicare

5 Clinical Nurse Specialist nurses found. Showing 1 - 5

Mrs. Dianne Woods, CRNP-PMH, APRN/PMH Clinical Nurse Specialist - Psych/Mental Health, Child & Adolescent Medicare: Medicare Enrolled Practice Location: 8818 Georgia Ave Fl 1, Silver Spring, MD 20910 Phone: 240-777-1450

Milka Taka, Clinical Nurse Specialist - Family Health Medicare: Medicare Enrolled Practice Location: 10801 Lockwood Dr Ste 300, Silver Spring, MD 20901 Phone: 301-681-0004    Fax: 301-593-1981

Dr. Blythe B. Bieging, PH.D. , A.P.R.N. Clinical Nurse Specialist - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 10230 New Hampshire Ave, Suite 202, Silver Spring, MD 20903 Phone: 301-431-1234    Fax: 301-439-5927

Roberta Worrall-feldhausen, APRN Clinical Nurse Specialist - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 3110 Gracefield Rd, Silver Spring, MD 20904 Phone: 301-572-8340    Fax: 301-572-8403

Mrs. Maureen B Fama, APRN Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Not Enrolled in Medicare Practice Location: 14809 Pennfield Cir, Silver Spring, MD 20906 Phone: 301-989-0143

News Archive

Cytokine GM-CSF likely plays important role in MS

Multiple sclerosis (MS) is caused by immune cells that activate a cascade of chemicals in the brain, attacking and degrading the insulation that keeps neuronal signals moving. These chemicals, called cytokines, drive the inflammation in the brain, attracting more immune cells, and causing the debilitating disease marked by loss of neurological function.

Side effects may limit use of Prometheus's Lotronex for IBS

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.

Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis

Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France's regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis' and Debiopharm's August 2009 license agreement, Curis will receive an $8 million milestone payment from Debiopharm for the achievement of this development objective.

AANS to hold its 79th Annual Scientific Meeting at Colorado Convention Center

The American Association of Neurological Surgeons will hold its 79th Annual Scientific Meeting at the Colorado Convention Center, April 9-13, 2011. The AANS is expected to host more than 6,000 attendees, with an estimated 3,000 medical professionals including neurosurgeons, neurosurgical residents, medical students, neuroscience nurses, clinical specialists, physician assistants and allied health professionals.

Comparative study finds three anti-seizure drugs to be equally safe and effective

A new study finds that the three most common treatment options administered in the emergency department for patients who experience refractory status epilepticus are equally safe and effective.

Read more Medical News

› Verified 7 days ago